Covaxin leh Covishield chawhpawlh zirchian remti

India rama vaccine pekchhuah kalpui meka vaccine hman tlanglawn ber pahnih, Covishield leh Covaxin chawhpawlh zirchianna neih chu Drugs Controller General Of India (DCGI) chuan a remti. Zirchianan leh clinical trial hi Christian Medical College, Vellore-in a nei ang.

"CMC Vellore (Tamil Nadu)-ah vaccine pahnih chawhpawlh tura zirchianna kalpui turin phalna kan pe a ni," tiin NITI Aayog Member (Health) Dr VK Paul chuan Thawhlehni khan press briefing-naah a sawi.

Subject Expert Committee of the Central Drugs Standard Control Organisation (CDSCO) chuan July 29 khan vaccine pahnih chawhpawlh hi zirchianna neih alo rawt tawh a ni.

He zirchianna hi Indian Council of Medical Research (ICMR) hnuaia zirchianna dang nen a danglam ang. ICMR hian Covid vaccine pahnih hman kawp hi a him zawk mai bakah natna kan do theihnate a tichak zawk niin a lo sawi tawh a ni. He enchhinnaah hian Uttar Pradesh hmarchhak lama cheng ṭhenkhat hnenah neih niin, Covishield chu dose khatna atan pein kar ruk hnuah dose hnihna atana Covaxin an pe thung. Heterologous group aṭangin mi 18 thlanchhuah an ni a, an zinga mi pahnih erawh chu an inhnukdawk leh a ni. An zinga mi 11 te chu mipa niin hmeichhia pasarih an ni a, an kum chawhrual hi kum 62 a ni.

ICMR zirchiannaah hian adenovirus vector platform-based vaccine lak zawha inactivated whole virus vaccine lak leh hi a him mai ni loin natna kan do theihna chak zawkin a insiam tih an hmuchhuak.

"Heterogeneous group leh homologous group inkarah khaikhinna kan nei a, kan hmuhchhuah chu natna kan do theihna a tichakin, miin Covishield an lak hmasak a, Covaxin an lak leh hian natna do theihna a tichak sawt zawk a ni. Adenovector leh whole variant vaccines chawhpawlha enchhinna kan neih hmasak ber a ni," tiin ICMR Epidemiology and Communicable Diseases hotu Dr Samiran Panda chuan a sawi.

Mi 18 hnenah chiah enchhinna hi kalpui a la nih vangin zirchianna zau zawk erawh kalpui zel a ngai dawn tih medical body lama hotute chuan an sawi bawk.